To include your compound in the COVID-19 Resource Center, submit it here.

Arvinas unveils first efficacy signal for targeted protein degradation, points to opportunity in resistant cancers

Arvinas’ top-line ASCO data provides the first evidence that targeted protein degraders can benefit patients, in particular those whose tumors have become resistant to standard therapies.

Founded by targeted degradation pioneer Craig Crews in 2013, Arvinas Inc. (NASDAQ:ARVN) has long been the torchbearer for the rapidly growing space. In October, the

Read the full 511 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers